Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Cartesian Therapeutics, Inc.
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
May 26, 2026
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 12, 2026
Cartesian Therapeutics Announces New Employment Inducement Grants
May 4, 2026
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
April 30, 2026
Cartesian Therapeutics Announces New Employment Inducement Grants
April 2, 2026
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
March 26, 2026